Protective HLA Class I Alleles That Restrict Acute-Phase CD8+ T-Cell Responses Are Associated with Viral Escape Mutations Located in Highly Conserved Regions of Human Immunodeficiency Virus Type 1

Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, USA.
Journal of Virology (Impact Factor: 4.65). 12/2008; 83(4):1845-55. DOI: 10.1128/JVI.01061-08
Source: PubMed

ABSTRACT The control of human immunodeficiency virus type 1 (HIV-1) associated with particular HLA class I alleles suggests that some CD8(+) T-cell responses may be more effective than others at containing HIV-1. Unfortunately, substantial diversities in the breadth, magnitude, and function of these responses have impaired our ability to identify responses most critical to this control. It has been proposed that CD8 responses targeting conserved regions of the virus may be particularly effective, since the development of cytotoxic T-lymphocyte (CTL) escape mutations in these regions may significantly impair viral replication. To address this hypothesis at the population level, we derived near-full-length viral genomes from 98 chronically infected individuals and identified a total of 76 HLA class I-associated mutations across the genome, reflective of CD8 responses capable of selecting for sequence evolution. The majority of HLA-associated mutations were found in p24 Gag, Pol, and Nef. Reversion of HLA-associated mutations in the absence of the selecting HLA allele was also commonly observed, suggesting an impact of most CTL escape mutations on viral replication. Although no correlations were observed between the number or location of HLA-associated mutations and protective HLA alleles, limiting the analysis to mutations selected by acute-phase immunodominant responses revealed a strong positive correlation between mutations at conserved residues and protective HLA alleles. These data suggest that control of HIV-1 may be associated with acute-phase CD8 responses capable of selecting for viral escape mutations in highly conserved regions of the virus, supporting the inclusion of these regions in the design of an effective vaccine.

Download full-text


Available from: Christian Brander, Sep 12, 2014
  • Source
    • "The 162 nt fragment belonging to 5 UTR which was not sequenced in this study is represented by a square with dotted line. A search of nucleotide conserved regions in IHHNV genome was performed in order to identify possible sites of genomic stability, which are often associated with viral infection and replication processes in different viruses (Wang et al., 2009; Kraft et al., 2013; Pollom et al., 2013). These regions are also ideal to PCR targeting especially in cases such as IHHNV which has a large number of variants. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A 3739 nucleotide fragment of Infectious Hypodermal and Hematopoietic Necrosis Virus (IHHNV) from Brazil was amplified and sequenced. This fragment contains the entire coding sequences of viral proteins, the full 3' untranslated region (3'UTR) and a partial sequence of 5' untranslated region (5'UTR). The genome organization of IHHNV revealed the three typical major coding domains: a left ORF1 of 2001bp that codes NS1, a left ORF2 (NS2) of 1091bp that codes NS2 and a right ORF3 of 990bp that codes VP. The nucleotide and amino acid sequences of the three viral proteins were compared with the putative amino acid sequences of viruses reported from different regions. Comparisons among genomes from different geographic regions reveal 31 nucleotide regions that are 100% similar, distributed throughout the genome. An analysis of secondary structure of the UTR regions, revealed regions with high probability to form hairpins, that may be involved in mechanisms of viral replication. Additionally a maximum likelihood analysis indicates that Brazilian IHHNV belongs to lineage III in the infectious IHHNV group, and is clustered with IHHNV isolates from Hawaii, China, Taiwan, Vietnam and South Korea. A new nested PCR targeting conserved nucleotide regions is proposed to detect IHHNV.
    Virus Research 05/2014; 189. DOI:10.1016/j.virusres.2014.05.008 · 2.83 Impact Factor
  • Source
    • "HLA allelic products contribute to immune control of viral infection through both innate and adaptive immune pathways (Carrington et al., 2008; Merino et al., 2012, 2013; Stewart et al., 2005). Alleles with early influences on HIV-1 infection tend to impose a strong selection pressure for viral immune escape mutations—a phenomenon that has been repeatedly examined in individuals with HLA-B n 57 and related alleles (Bansal et al., 2007; Crawford et al., 2009; Leslie et al., 2004; Novitsky et al., 2010; Wang et al., 2009). The unfavorable effect of HLA-B n 18 on VL started early and remained stable (Fig. 1), which may translate to a durable impact on HIV-1 pathogenesis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In HIV-1 infection, plasma viral load (VL) has dual implications for pathogenesis and public health. Based on well-known patterns of HIV-1 evolution and immune escape, we hypothesized that VL is an evolving quantitative trait that depends heavily on duration of infection (DOI), demographic features, human leukocyte antigen (HLA) genotypes and viral characteristics. Prospective data from 421 African seroconverters with at least four eligible visits did show relatively steady VL beyond 3 months of untreated infection, but host and viral factors independently associated with cross-sectional and longitudinal VL often varied by analytical approaches and sliding time windows. Specifically, the effects of age, HLA-B⁎53 and infecting HIV-1 subtypes (A1, C and others) on VL were either sporadic or highly sensitive to time windows. These observations were strengthened by the addition of 111 seroconverters with 2–3 eligible VL results, suggesting that DOI should be a critical parameter in epidemiological and clinical studies.
    Virology 01/2014; 449:254–262. DOI:10.1016/j.virol.2013.11.024 · 3.28 Impact Factor
  • Source
    • "However, it would be clearly advantageous to target epitopes that are both conserved across different HIV subtypes (Goulder et al. 1996; Turnbull et al. 2006) and also sequence limited by viral fitness constraints (Martinez-Picado et al. 2006; Schneidewind et al. 2007). As mentioned above, the striking association between the expression of particular MHC alleles and virologic outcome speaks to a role for CD8 T cells in the control of viral replication (Kaslow et al. 1996; Hendel et al. 1999; Migueles et al. 2000; Gao et al. 2001), but the mechanisms underlying such protective effects remain poorly understood save for the presentation by particular MHC alleles of particular epitopes that are conserved owing to fitness constraints (Wang et al. 2009) and diversity in the T-cell receptor repertoire that targets such epitopes (Simons et al. 2008; Geldmacher et al. 2009). Although TCR diversity may seem an obvious advantage when targeting a virus that undergoes mutational epitope escape, studies in SIV-infected rhesus macaques have shown that the beneficial virologic outcome conferred by expression of the MHC allele Mamu A Ã 01 may be mediated by the use of particular TCRs that target an immunodominant epitope (Price et al. 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Vaccines are arguably the most powerful medical intervention in the fight against infectious diseases. The enormity of the global human immunodeficiency virus type 1 (HIV)/acquired immunodeficiency syndrome (AIDS) pandemic makes the development of an AIDS vaccine a scientific and humanitarian priority. Research on vaccines that induce T-cell immunity has dominated much of the recent development effort, mostly because of disappointing efforts to induce neutralizing antibodies through vaccination. Whereas T cells are known to limit HIV and other virus infections after infection, their role in protection against initial infection is much less clear. In this article, we will review the rationale behind a T-cell-based vaccine approach, provide an overview of the methods and platforms that are being applied, and discuss the impact of recent vaccine trial results on the future direction of T-cell vaccine research.
    Cold Spring Harbor Perspectives in Medicine 09/2011; 1(1):a007252. DOI:10.1101/cshperspect.a007252 · 7.56 Impact Factor
Show more